4-Fluoro-N-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Fluoro-N-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-benzamide
• 英文别名: 4-fluoro-N-[1-(4-fluorophenyl)sulfonylpiperidin-4-yl]benzamide
• 化学式: C₁₈H₁₈F₂N₂O₃S
• 分子量: 380.4
• InChiKey: LNFVUIQBFNNQFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property
  申请人：——

  公开号：US20040092528A1

  公开（公告）日：2004-05-13

  The present invention relates to an agent for modulating excitatory synaptic transmission which contains a compound having &agr;7 nicotinic acetylcholine receptor activation property as an active ingredient, and the production of such an agent. It further relates to a pharmaceutical composition which contains such a compound together with a pharmaceutically acceptable carrier or excipient, and a method for modulating excitatory synaptic transmission which comprises administering such a composition. There is also provided a method for screening an agent for modulating excitatory synaptic transmission which comprises using &agr;7 nicotinic acetylcholine receptor activation property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases, including dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease and psychosomatic disease.

  本发明涉及一种调节兴奋性突触传递的药剂，其含有具有α7尼古丁乙酰胆碱受体激活性质的化合物作为活性成分，以及制备该药剂的方法。它还涉及一种药物组合物，其中包含该化合物和药学上可接受的载体或赋形剂，以及一种调节兴奋性突触传递的方法，包括给予这样的组合物。还提供了一种用α7尼古丁乙酰胆碱受体激活性质作为指标的筛选调节兴奋性突触传递的药剂的方法。本发明对于预防和/或治疗包括痴呆症、遗忘症、躁郁症、精神分裂症、帕金森病和心身疾病在内的脑部疾病非常有用。
• AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1235575A2

  公开（公告）日：2002-09-04
• AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1315494A1

  公开（公告）日：2003-06-04
• [EN] AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY<br/>[FR] AGENT POUR L'EXPRESSION DE LA POTENTIALISATION A LONG TERME DE LA TRANSMISSION SYNAPTIQUE, COMPRENANT UN COMPOSE POSSEDANT LA PROPRIETE D'ACTIVER LA SOMATOSTATINE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2000072834A2

  公开（公告）日：2000-12-07

  The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a somatostatin releasing property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.
• [EN] AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA alpha 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY<br/>[FR] AGENT DE MODULATION DE LA TRANSMISSION SYNAPTIQUE EXCITATRICE COMPRENANT UN COMPOSE DOTE D'UNE PROPRIETE D'ACTIVATION DU RECEPTEUR D'ACETYLCHOLINE NICOTINIQUE ALPHA DOLLAR G(A)7
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002020016A1

  公开（公告）日：2002-03-14

  The present invention relates to an agent for modulating excitatory synaptic transmission which contains a compound having α7 nicotinic acetylcholine receptor activation property as an active ingredient, and the production of such an agent. It further relates to a pharmaceutical composition which contains such a compound together with a pharmaceutically acceptable carrier or excipient, and a method for modulating excitatory synaptic transmission which comprises administering such a composition. There is also provided a method for screening an agent for modulating excitatory synaptic transmission which comprises using α7 nicotinic acetylcholine receptor activation property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases, including dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease and psychosomatic disease.